Replies to post #6175 on Algernon Pharmaceuticals Inc (AGNPF)

[shell3]

Algernon became Unlimited Authorization last March or so

Probably not this time but as shown — Might keep selling them to fund things

[Money $hot]

There's a belief at corporate that Algernon can be a viable penny stock up to 300 Million shares. If fully diluted now, Algernon is nearly halfway there. It remains my belief common shareholders pre split have one shot at recovery of losses. Surely, if the IPF trial fails and/or Algernon manages to strike a lowball deal with big pharma, there will be another attempt to raise money. Unfortunately, Algernon went from 3 trials @ $5 Million CAD - capital raise - to 1 trial @ $3.5 Million CAD. Those numbers are wildly different from an investment standpoint. More specifically, common shareholders continue to get clobbered. One can only hope Algernon will live up to the latest timeline.

MD&A

The Company is planning the following milestones:

2020
Q1 Submit for ethics in Australia for phase 2 IPF/cough study
Publish research papers IBD & IPF/cough

Q2 Receive ethics approval for phase 2 IPF/cough study
First patient enrolled in phase 2 IPF/cough study

Q4 Possible early data from chronic cough endpoint

2021
Q1 Final data from IPF/cough study

There are some things current management has done well. However, it does not outweigh all the falsehoods and failures to date.

Meanwhile...

/////AMG